Inactive Instrument

Portola Pharmaceuticals, Inc.

Equities

US7370101088

Biotechnology & Medical Research

Portola Pharmaceuticals, Inc. Suspends Prior Guidance for Approximately 350 New Hospital Adds in 2020

May 11, 2020 at 08:00 am EDT

Portola Pharmaceuticals, Inc. suspending prior guidance for approximately 350 new hospital adds in 2020. With the uncertainty around the duration of COVID-19 impacts, Portola is suspending prior guidance provided during its fourth quarter 2019 call for approximately 350 new hospital adds in 2020.

Latest news about Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc.(NasdaqGS:PTLA) dropped from S&P Biotechnology Select Industry Index	20-07-02	CI
Portola Pharmaceuticals, Inc.(NasdaqGS:PTLA) dropped from S&P TMI Index	20-07-02	CI
Portola Pharmaceuticals, Inc.(NasdaqGS:PTLA) dropped from S&P Global BMI Index	20-07-02	CI
Alexion Pharmaceuticals, Inc. completed the acquisition of the remaining 96.6% stake in Portola Pharmaceuticals, Inc..	20-06-30	CI
Portola Pharmaceuticals, Inc. Receives Written Notice of Termination from Bayer AG	20-06-17	CI
Portola Pharmaceuticals, Inc. Suspends Prior Guidance for Approximately 350 New Hospital Adds in 2020	20-05-11	CI
Portola Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-11	CI
Alexion Pharmaceuticals, Inc. entered into non-binding expression of interest to acquire remaining 96.6% stake in Portola Pharmaceuticals, Inc. for $1.4 billion.	20-05-04	CI
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer, Inc. Aggress to Terminate the Collaboration and License Agreement Among the Parties	20-04-09	CI
Portola Pharmaceuticals, Inc. Announces the Establishment of Permanent J-Code for Andexxa by the Centers for Medicare & Medicaid Services, Effective July 1, 2020	20-04-07	CI
Portola Pharmaceuticals, Inc. Announces Results Demonstrating Andexxa® Was Associated with Low Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds	20-03-16	CI
New Data Demonstrates Andexxa Can Provide Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors	20-03-05	CI
Transcript : Portola Pharmaceuticals, Inc., Q4 2019 Earnings Call, Feb 26, 2020	20-02-26
Portola Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019	20-02-26	CI
Portola Pharmaceuticals, Inc. Reports Impairment Charge for the Fourth Quarter Ended Dec. 31, 2019	20-02-26	CI
Portola Pharmaceuticals, Inc. Announces Executive Changes	20-02-03	CI
Transcript : Portola Pharmaceuticals, Inc. - Special Call	20-01-14
Transcript : Portola Pharmaceuticals, Inc., Q4 2019 Guidance/Update Call, Jan 09, 2020	20-01-09
Portola Pharmaceuticals, Inc. Announces Revenue Guidance for the Fourth Quarter and Full Year 2019	20-01-09	CI
Portola Pharmaceuticals Presents New Interim Data at the 61st ASH Meeting on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma	19-12-09	CI
Portola Pharmaceuticals, Inc. Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies	19-12-08	CI
Transcript : Portola Pharmaceuticals, Inc. - Analyst/Investor Day	19-11-14
Certain Common Stock of Portola Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 12-NOV-2019.	19-11-11	CI
Certain Options of Portola Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 12-NOV-2019.	19-11-11	CI
Certain Warrants of Portola Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 12-NOV-2019.	19-11-11	CI

Chart Portola Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research